Ultra-long-acting (XLA) antivirals for chronic viral hepatitis

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis

ABSTRACT: Viral hepatitis is among the top four causes of mortality globally, causing 1.4 million deaths each year, exceeding tuberculosis, malaria and human immunodeficiency virus. Hepatitis B and C are responsible for 90% of hepatitis deaths, and the remaining 10% are caused by other hepatitis vir...

Full description

Bibliographic Details
Main Authors:	Vicente Soriano, Carmen Alvarez, Benson Edagwa, Carmen de Mendoza, Noemí Montoya, Ana Treviño, Howard Gendelman
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	International Journal of Infectious Diseases
Subjects:	Viral hepatitis Long-acting antivirals Chemical vaccines Hepatitis B Hepatitis C Hepatitis D
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971221008390

Similar Items

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
by: Erica Nicola Lynch, et al.
Published: (2023-03-01)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
by: Hsu-Heng Yen, et al.
Published: (2021-03-01)

Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C
by: A. I. Gubenko, et al.
Published: (2023-12-01)

New antiviral agents and new treatments on the horizon for the management of viral hepatitis
by: M. Sönmezoğlu
Published: (2011-12-01)

The Outcomes of Direct-acting Antiviral Treatment in 177 Patients with Hepatitis C Virus: A Single-center Experience
by: Ayşin KILINÇ TOKER, et al.
Published: (2023-12-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
by: Christiana Graf, et al.
Published: (2020-08-01)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
by: Soon Young Ko, et al.
Published: (2018-12-01)

Antiviral therapy in chronic hepatitis C virus infection
by: Irina Russu
Published: (2019-09-01)

Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis
by: Joo Hyun Oh, et al.
Published: (2022-11-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
by: Byung Soo Kwan, et al.
Published: (2021-03-01)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01)

Prevention of Viral Hepatitis
by: Neşe SALTOĞLU
Published: (2001-09-01)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
by: Chung-Feng Huang, et al.
Published: (2020-07-01)

Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center
by: L.P. Zanaga, et al.

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
by: Paweł Pabjan, et al.
Published: (2022-01-01)

Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals
by: Satoshi Takakusagi, et al.
Published: (2022-04-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

EFFECT OF ANTIVIRAL THERAPY ON CARDIOHEMODYNAMIC INDICATORS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS AND LIVER CIRRHOSIS
by: M. V. Chistyakova, et al.
Published: (2017-01-01)

Current status and strategies for viral hepatitis control in Korea
by: Dong Hyun Sinn, et al.
Published: (2017-09-01)

Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
by: Mohit Bhatia, et al.
Published: (2020-01-01)

Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
by: Mathias Jachs, et al.
Published: (2023-08-01)

Assessment of serum Resistin in detecting Insulin Resistance and their impact on response to direct acting antiviral in chronic viral hepatitis C patients
by: Amira Isaac, et al.
Published: (2021-08-01)

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C
by: Kuo-Tung Tang, et al.
Published: (2022-09-01)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
by: Kazuto Tajiri, et al.
Published: (2023-05-01)

Features of Treatment of Patients Infected with Hepatitis C Virus Genotypes 1 And 4 by Direct-Acting Antiviral Drugs
by: V.P. Shypulin, et al.
Published: (2016-09-01)

Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
by: Chen-Hua Liu, et al.
Published: (2020-12-01)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
by: Naim Abu-Freha, et al.
Published: (2023-09-01)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019-01-01)

Marcadores virales de la hepatitis
by: Carlos Fardella B., et al.
Published: (2017-05-01)

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer
by: Ryoko Kuromatsu, et al.
Published: (2022-05-01)

Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil
by: Vinicius Lins Ferreira, et al.

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
by: Nevine Ibrahim Musa, et al.
Published: (2020-07-01)

Viral hepatitis surveillance in Sri Lanka
by: D. A. C. L. Amarasinghe, et al.
Published: (2004-12-01)

Epidemiological profile of viral hepatitis infection in the population treated at a reference hospital in Alagoas
by: K. M. da Silva, et al.
Published: (2021-06-01)

Antiviral activity of zinc against hepatitis viruses: current status and future prospects
by: Shiv Kumar, et al.
Published: (2023-10-01)

Collaborative Referral Model for Hepatitis C Screening and Treatment in a Remote Mountainous Region of Taiwan during the COVID-19 Pandemic
by: Chi-Ming Tai, et al.
Published: (2023-03-01)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
by: Pil Soo Sung, et al.
Published: (2021-01-01)